TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Featured:

Jean-Jacques KiladjianJean-Jacques KiladjianStefan N. ConstantinescuStefan N. ConstantinescuTiziano BarbuiTiziano BarbuiLaura MichaelisLaura MichaelisHaifa Kathrin Al-AliHaifa Kathrin Al-AliSteffen KoschmiederSteffen Koschmieder

May 18, 2023

Learning objective: After reading this article, learners will be able to cite a new preclinical development in myeloproliferative neoplasms.


The MPN Hub invited Stefan Constantinescu, De Duve Institute, Brussels, BE, to give a presentation and chair a discussion on his research paper: Secreted mutant calreticulins (CALRs) as rogue cytokines in myeloproliferative neoplasms. MPN Hub Steering Committee members Jean-Jacques Kiladjian, Steffen Koschmieder, Haifa Kathrin Al-Ali, Tiziano Barbui, and Laura Michaelis joined the discussion.

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Constantinescu opens by providing a background on mutant CALRs and outlining the key questions this international study aimed to answer, including whether mutant CALRs are secreted and from which cells.1 Constantinescu goes on to review the results data and the implications the findings may have on future research in myeloproliferative neoplasms. Following this presentation, the committee members discuss the study and the unanswered questions remaining around mutant CALRs.

References

Your opinion matters

On average, how many patients with myelofibrosis do you see in a month?